FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4310709611> ?p ?o ?g. }

• W4310709611 endingPage "41" @default.
• W4310709611 startingPage "36" @default.
• W4310709611 abstract "Establishment of drug testing of patient-derived cancer cells (PDCs) in physiologically relevant 3-dimensional (3D) culture is central for drug discovery and cancer research, as well as for functional precision medicine. Here, we describe the detailed protocol allowing the 3D drug testing of PDCs – or any type of cells of interest – in Matrigel in 384-well plate format using automation. We also provide an alternative protocol, which does not require supporting matrices. The cancer tissue is obtained directly from clinics (after surgery or biopsy) and processed into single cell suspension. Systematic drug sensitivity and resistance testing (DSRT) is carried out on the PDCs directly after cancer cell isolation from tissue or on cells expanded for a few passages. In the 3D-DSRT assay, the PDCs are plated in 384-well plates in Matrigel, grown as spheroids, and treated with compounds of interest for 72 h. The cell viability is directly measured using a luminescence-based assay. Alternatively, prior to the cell viability measurement, drug-treated cells can be directly subjected to automated high-content bright field imaging or stained for fluorescence (live) cell microscopy for further image analysis. This is followed by the quality control and data analysis. The 3D-DSRT can be performed within a 1–3-week timeframe of the clinical sampling of cancer tissue, depending on the amount of the obtained tissue, growth rate of cancer cells, and the number of drugs being tested. The 3D-DSRT method can be flexibly modified, e.g., to be carried out with or without supporting matrices with U-bottom 384-well plates when appropriate for the PDCs or other cell models used." @default.
• W4310709611 created "2022-12-16" @default.
• W4310709611 creator A5003065165 @default.
• W4310709611 creator A5033369123 @default.
• W4310709611 creator A5047848282 @default.
• W4310709611 creator A5053034632 @default.
• W4310709611 creator A5060810486 @default.
• W4310709611 creator A5079297101 @default.
• W4310709611 creator A5081860537 @default.
• W4310709611 creator A5089980412 @default.
• W4310709611 date "2023-03-01" @default.
• W4310709611 modified "2023-10-14" @default.
• W4310709611 title "Protocol for 3D drug sensitivity and resistance testing of patient-derived cancer cells in 384-well plates" @default.
• W4310709611 cites W1998914462 @default.
• W4310709611 cites W2002783575 @default.
• W4310709611 cites W2017521095 @default.
• W4310709611 cites W2103177188 @default.
• W4310709611 cites W2156732033 @default.
• W4310709611 cites W2261944919 @default.
• W4310709611 cites W2295223477 @default.
• W4310709611 cites W2331628193 @default.
• W4310709611 cites W2346294150 @default.
• W4310709611 cites W2471907651 @default.
• W4310709611 cites W2520107693 @default.
• W4310709611 cites W2554439427 @default.
• W4310709611 cites W2601380465 @default.
• W4310709611 cites W2602807759 @default.
• W4310709611 cites W2626725994 @default.
• W4310709611 cites W2742005115 @default.
• W4310709611 cites W2781664750 @default.
• W4310709611 cites W2888456379 @default.
• W4310709611 cites W3010256878 @default.
• W4310709611 cites W3084720999 @default.
• W4310709611 cites W3104198951 @default.
• W4310709611 cites W3128579898 @default.
• W4310709611 cites W3133726036 @default.
• W4310709611 cites W3190107426 @default.
• W4310709611 cites W3200678711 @default.
• W4310709611 cites W3214427435 @default.
• W4310709611 cites W3217527321 @default.
• W4310709611 doi "https://doi.org/10.1016/j.slasd.2022.11.003" @default.
• W4310709611 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36464160" @default.
• W4310709611 hasPublicationYear "2023" @default.
• W4310709611 type Work @default.
• W4310709611 citedByCount "2" @default.
• W4310709611 countsByYear W43107096112023 @default.
• W4310709611 crossrefType "journal-article" @default.
• W4310709611 hasAuthorship W4310709611A5003065165 @default.
• W4310709611 hasAuthorship W4310709611A5033369123 @default.
• W4310709611 hasAuthorship W4310709611A5047848282 @default.
• W4310709611 hasAuthorship W4310709611A5053034632 @default.
• W4310709611 hasAuthorship W4310709611A5060810486 @default.
• W4310709611 hasAuthorship W4310709611A5079297101 @default.
• W4310709611 hasAuthorship W4310709611A5081860537 @default.
• W4310709611 hasAuthorship W4310709611A5089980412 @default.
• W4310709611 hasBestOaLocation W43107096111 @default.
• W4310709611 hasConcept C121608353 @default.
• W4310709611 hasConcept C126322002 @default.
• W4310709611 hasConcept C136229726 @default.
• W4310709611 hasConcept C142724271 @default.
• W4310709611 hasConcept C1491633281 @default.
• W4310709611 hasConcept C163688615 @default.
• W4310709611 hasConcept C185592680 @default.
• W4310709611 hasConcept C2778076430 @default.
• W4310709611 hasConcept C2778608917 @default.
• W4310709611 hasConcept C2780035454 @default.
• W4310709611 hasConcept C502942594 @default.
• W4310709611 hasConcept C53227056 @default.
• W4310709611 hasConcept C54355233 @default.
• W4310709611 hasConcept C55493867 @default.
• W4310709611 hasConcept C71924100 @default.
• W4310709611 hasConcept C81885089 @default.
• W4310709611 hasConcept C86803240 @default.
• W4310709611 hasConcept C96232424 @default.
• W4310709611 hasConcept C98274493 @default.
• W4310709611 hasConceptScore W4310709611C121608353 @default.
• W4310709611 hasConceptScore W4310709611C126322002 @default.
• W4310709611 hasConceptScore W4310709611C136229726 @default.
• W4310709611 hasConceptScore W4310709611C142724271 @default.
• W4310709611 hasConceptScore W4310709611C1491633281 @default.
• W4310709611 hasConceptScore W4310709611C163688615 @default.
• W4310709611 hasConceptScore W4310709611C185592680 @default.
• W4310709611 hasConceptScore W4310709611C2778076430 @default.
• W4310709611 hasConceptScore W4310709611C2778608917 @default.
• W4310709611 hasConceptScore W4310709611C2780035454 @default.
• W4310709611 hasConceptScore W4310709611C502942594 @default.
• W4310709611 hasConceptScore W4310709611C53227056 @default.
• W4310709611 hasConceptScore W4310709611C54355233 @default.
• W4310709611 hasConceptScore W4310709611C55493867 @default.
• W4310709611 hasConceptScore W4310709611C71924100 @default.
• W4310709611 hasConceptScore W4310709611C81885089 @default.
• W4310709611 hasConceptScore W4310709611C86803240 @default.
• W4310709611 hasConceptScore W4310709611C96232424 @default.
• W4310709611 hasConceptScore W4310709611C98274493 @default.
• W4310709611 hasFunder F4320321108 @default.
• W4310709611 hasFunder F4320321726 @default.
• W4310709611 hasFunder F4320326591 @default.
• W4310709611 hasIssue "2" @default.

• next